A.W.S. Ritchie - Concepedia

Author

A.W.S. Ritchie

Also Known As

A RITCHIE, A Ritchie, A W Ritchie, A W S Ritchie, A. Ritchie, A. W. S. RITCHIE, A. W. S. Ritchie, A.W.S. RITCHIE, A.W.S. Ritchie, ALASTAIR W.S. RITCHIE

120

Publications

9.1K

Citations

H-Index

Concepts

All Affiliations

University College London MRC Clinical Trials Unit at UCL Institute of Cancer Research Western General Hospital Velindre Cancer Centre

About

A.W.S. Ritchie is an author at University College London specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	29	1.4K
2	Cell Biology	4	4	187
3	Health Sciences	2	2	72
4	Allergy	2	2	267
5	Public Health	1	1	134

A.W.S. Ritchie

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Nicholas D. James, Matthew R. Sydes, Noel W. Clarke, The Lancet	2015	1.9K
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy Nicholas D. James, Johann S. de Bono, Melissa Spears, New England Journal of Medicine	2017	1.7K
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Christopher Parker, Nicholas D. James, Chris Brawley, The Lancet	2018	1.2K
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Nicholas D. James, Melissa Spears, Noel W. Clarke, European Urology	2014	431
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial N.W. Clarke, Amin Ali, Fiona C. Ingleby, Annals of Oncology	2019	389
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol Matthew R. Sydes, Melissa Spears, Malcolm D. Mason, Annals of Oncology	2018	240
Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex Hoyle, Adnan Ali, Nicholas D. James, European Urology UrologyMedicine“ High- ”PharmacotherapyProstatic Disease	2019	199
Circadian variation of lymphocyte subpopulations: a study with monoclonal antibodies. A.W.S. Ritchie, Isabelle P. Oswald, H. S. Micklem, BMJ Laboratory ImmunologyCircadian VariationImmunologyImmunotherapyNeuroimmunology	1983	193
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer Nicholas D. James, Melissa Spears, Noel W. Clarke, JAMA Oncology	2015	182
The natural history of renal carcinoma. A.W.S. Ritchie, G. D. Chisholm PubMed	1983	172

Page 1